# US 2020/0002389 A1 · Transdermal peptide with nuclear localization ability and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0002389 A1
- Document ID: US20200002389A1
- Status: Published application
- Kind: A1
- Application number: 16/484,153
- Filed: 2017-09-30
- Published: 2020-01-02
- Earliest claimed: 2017-09-05
- Assignees: Soochow University
- Applicants: Soochow University
- Inventors: Shuyu ZHANG; Jianping CAO; Daojiang YU; Wei ZHU
- Web page: https://patentgrep.com/patent/US20200002389A1

## CPC

- C07K 14/47: from mammals
- A61K 47/42: Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein (oligopeptides having up to five amino acids {A61K47/183}; polyamino acids A61K47/34)
- A61K 47/62: the modifying agent being a protein, peptide or polyamino acid
- A61K 49/0043: {Fluorescein, used in vivo}
- A61K 49/0056: {Peptides, proteins, polyamino acids}
- A61P 17/00: Drugs for dermatological disorders
- C07K 14/00: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C12N 9/0089: {acting on superoxide as acceptor (1.15)}
- C12Y 115/01001: Superoxide dismutase (1.15.1.1)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/09: containing a nuclear localisation signal
- C07K 2319/60: containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
- C12N 9/18: Carboxylic ester hydrolases {(3.1.1)}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

The invention relates to a transdermal peptide with a nuclear localization ability and having an amino acid sequence as shown in SEQ ID NO: 1. The invention provides a fusion protein with a nuclear localization ability, which comprises a macromolecular protein with one end being linked to the transdermal peptide. The invention also discloses the use of the transdermal peptide in the preparation of a medicament or a transdermal preparation for treating skin diseases. The invention further provides a medicament for treating a skin disease, comprising the transdermal peptide and a pharmaceutically acceptable excipient. The transdermal peptide enters the cells autonomously to locate in the nuclei, and can penetrate through the stratum corneum of the skin into cells in the dermis. The peptide is conveniently synthesized artificially and suitable for transdermal administration, and has a therapeutic potential via transdermal administration by carrying a drug for treating skin diseases.

## Claims

### Claim 1

A transdermal peptide with a nuclear localization ability, having an amino acid sequence as shown in SEQ ID NO: 1, wherein the transdermal peptide enters the eukaryotic cells autonomously.

### Claim 2 (depends on 1)

The transdermal peptide according to claim 1, wherein the transdermal peptide is further linked to fluorescein.

### Claim 3 (depends on 2)

The transdermal peptide according to claim 2, wherein the fluorescein is fluorescein isothiocyanate, rhodamine or carboxyfluorescein (FAM).

### Claim 4 (depends on 1)

The transdermal peptide according to claim 1, wherein the eukaryotic cells are HaCaT cells, WS1 cells, TE-1 cells, Eca-109 cells, or HeLa cells.

### Claim 5 (depends on 1)

A fusion protein with a nuclear localization ability, comprising a macromolecular protein, one end of which is linked to the transdermal peptide according to claim 1.

### Claim 6 (depends on 5)

The fusion protein with a nuclear localization ability according to claim 5, wherein the other end of the macromolecular protein is linked to a fluorescent protein.

### Claim 7 (depends on 5)

The fusion protein with a nuclear localization ability according to claim 5, wherein the macromolecular protein has a molecular weight of 10-50 KD.

### Claim 8 (depends on 5)

The fusion protein with a nuclear localization ability according to claim 5, wherein the macromolecular protein has an amino acid sequence as shown in SEQ ID NO: 2, and the macromolecular protein is human superoxide dismutase.

### Claim 9 (depends on 1)

Use of the transdermal peptide according to claim 1 in the preparation of a medicament or a transdermal preparation for treating skin diseases.

### Claim 10 (depends on 1)

A medicament for treating a skin disease, comprising the transdermal peptide according to claim 1 and a pharmaceutically acceptable excipient.
